三联疗法-话题@MedSci

#三联疗法#

56篇内容 | 2206人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1613706, encodeId=cd1e1613e06f2, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=54, createdTime=2018-04-30, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613705, encodeId=b8021613e0563, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Hp相关慢性胃炎或消化性溃疡相关荟萃分析：荆花胃康+PPI 三联疗法的有效性和安全性, objectType=article, longId=122995, objectId=3825122995b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3825122995b9, replyNumber=0, likeNumber=65, createdTime=2017-12-12, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3825122995b9, moduleTitle=Hp相关慢性胃炎或消化性溃疡相关荟萃分析：荆花胃康+PPI 三联疗法的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3825122995b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613704, encodeId=a06f1613e0443, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Eur J Clin Pharmacol：益生菌联合三联疗法治疗儿童幽门螺杆菌感染, objectType=article, longId=119555, objectId=c10f11955573, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c10f11955573, replyNumber=0, likeNumber=164, createdTime=2017-11-12, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c10f11955573, moduleTitle=Eur J Clin Pharmacol：益生菌联合三联疗法治疗儿童幽门螺杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c10f11955573)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613703, encodeId=f2241613e036b, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Ann Intern Med：三联疗法与生物疗法治疗活动性类风湿关节炎患者的成本效益比较分析, objectType=article, longId=100184, objectId=de74100184d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de74100184d0, replyNumber=0, likeNumber=37, createdTime=2017-06-01, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de74100184d0, moduleTitle=Ann Intern Med：三联疗法与生物疗法治疗活动性类风湿关节炎患者的成本效益比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de74100184d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613702, encodeId=f86d1613e02b5, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Lancet：单次吸入超细三联疗法与长效毒蕈碱受体拮抗剂治疗慢性阻塞性肺疾病哪个好？, objectType=article, longId=94661, objectId=450094661dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=450094661dd, replyNumber=0, likeNumber=65, createdTime=2017-04-06, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=450094661dd, moduleTitle=Lancet：单次吸入超细三联疗法与长效毒蕈碱受体拮抗剂治疗慢性阻塞性肺疾病哪个好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=450094661dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613701, encodeId=0da91613e012b, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, objectType=article, longId=77492, objectId=45e5e749218, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45e5e749218, replyNumber=0, likeNumber=55, createdTime=2016-09-16, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45e5e749218, moduleTitle=Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45e5e749218)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613700, encodeId=0a251613e009b, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, objectType=article, longId=77042, objectId=be26e7042b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be26e7042b9, replyNumber=0, likeNumber=38, createdTime=2016-09-10, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be26e7042b9, moduleTitle=ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be26e7042b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613699, encodeId=6f54161369921, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, objectType=article, longId=70647, objectId=2a45e0647b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a45e0647b2, replyNumber=0, likeNumber=59, createdTime=2016-06-15, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a45e0647b2, moduleTitle=EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a45e0647b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613698, encodeId=70131613698cb, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Am J Gastroenterol：幽门螺杆菌根除治疗新秀——钾竞争酸阻滞剂（P-CAB）疗效优于PPI三联疗法, objectType=article, longId=68963, objectId=502868963bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=502868963bf, replyNumber=0, likeNumber=88, createdTime=2016-05-25, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=502868963bf, moduleTitle=Am J Gastroenterol：幽门螺杆菌根除治疗新秀——钾竞争酸阻滞剂（P-CAB）疗效优于PPI三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=502868963bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613697, encodeId=0f49161369e78, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Am J Gastroenterol：幽门螺旋杆菌的二线治疗：左氧氟沙星序贯疗法优于三联疗法, objectType=article, longId=63362, objectId=5cc66336253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cc66336253, replyNumber=0, likeNumber=81, createdTime=2016-02-18, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cc66336253, moduleTitle=Am J Gastroenterol：幽门螺旋杆菌的二线治疗：左氧氟沙星序贯疗法优于三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cc66336253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613696, encodeId=440616136968f, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=JACC：老年房颤患者急性心肌梗死的三联疗法的应用及疗效, objectType=article, longId=54420, objectId=b9fc544206e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9fc544206e, replyNumber=0, likeNumber=80, createdTime=2015-08-06, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9fc544206e, moduleTitle=JACC：老年房颤患者急性心肌梗死的三联疗法的应用及疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9fc544206e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613695, encodeId=823c161369531, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=PLoS One：三联疗法可增强神经胶质瘤的免疫反应, objectType=article, longId=39097, objectId=22293909ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22293909ee0, replyNumber=0, likeNumber=87, createdTime=2014-08-16, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22293909ee0, moduleTitle=PLoS One：三联疗法可增强神经胶质瘤的免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22293909ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613694, encodeId=7d131613694ff, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, objectType=article, longId=38150, objectId=2fcf38150b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcf38150b2, replyNumber=0, likeNumber=54, createdTime=2014-07-25, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcf38150b2, moduleTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcf38150b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613693, encodeId=17aa161369371, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=EASL 2014：FDV+DBV+ PPI-668的三联疗法可获得较高SVR率, objectType=article, longId=34698, objectId=1cb0346988f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cb0346988f, replyNumber=0, likeNumber=90, createdTime=2014-05-15, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cb0346988f, moduleTitle=EASL 2014：FDV+DBV+ PPI-668的三联疗法可获得较高SVR率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cb0346988f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613692, encodeId=907e1613692c0, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Hepatology：含SMV三联疗法治疗慢性1型丙肝安全有效, objectType=article, longId=30676, objectId=985c306e633, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=985c306e633, replyNumber=0, likeNumber=50, createdTime=2014-02-16, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=985c306e633, moduleTitle=Hepatology：含SMV三联疗法治疗慢性1型丙肝安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=985c306e633)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613691, encodeId=a1e116136917e, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战, objectType=article, longId=27376, objectId=329c2e376fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329c2e376fa, replyNumber=0, likeNumber=132, createdTime=2013-12-02, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329c2e376fa, moduleTitle=Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=329c2e376fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613690, encodeId=9fc61613690e5, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核, objectType=article, longId=25136, objectId=6c3e25136ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c3e25136ce, replyNumber=0, likeNumber=67, createdTime=2013-10-01, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c3e25136ce, moduleTitle=CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c3e25136ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613689, encodeId=9adc1613689ce, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗, objectType=article, longId=20744, objectId=2e7920e44ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e7920e44ae, replyNumber=0, likeNumber=68, createdTime=2013-07-03, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e7920e44ae, moduleTitle=含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e7920e44ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

三联疗法

2020-05-29

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Vertex在III期临床试验中测试CF三联疗法

2018-04-30

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Hp相关慢性胃炎或消化性溃疡相关荟萃分析：荆花胃康+PPI 三联疗法的有效性和安全性

2017-12-12

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Eur J Clin Pharmacol：益生菌联合三联疗法治疗儿童幽门螺杆菌感染

2017-11-12

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Ann Intern Med：三联疗法与生物疗法治疗活动性类风湿关节炎患者的成本效益比较分析

2017-06-01

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Lancet：单次吸入超细三联疗法与长效毒蕈碱受体拮抗剂治疗慢性阻塞性肺疾病哪个好？

2017-04-06

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据

2016-09-16

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

ERS 2016：葛兰素史克慢性阻塞性肺病（COPD）三联疗法FF/UMEC/VI头对头III期临床疗效击败阿斯利康Symbicort turbohaler

2016-09-10

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

EHA 2016：强生多发性骨髓瘤药物Darzalex+来那度胺+地塞米松三联疗法III期临床显著延长无进展生存期

2016-06-15

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Am J Gastroenterol：幽门螺杆菌根除治疗新秀——钾竞争酸阻滞剂（P-CAB）疗效优于PPI三联疗法

2016-05-25

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Am J Gastroenterol：幽门螺旋杆菌的二线治疗：左氧氟沙星序贯疗法优于三联疗法

2016-02-18

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

JACC：老年房颤患者急性心肌梗死的三联疗法的应用及疗效

2015-08-06

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

PLoS One：三联疗法可增强神经胶质瘤的免疫反应

2014-08-16

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）

2014-07-25

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

EASL 2014：FDV+DBV+ PPI-668的三联疗法可获得较高SVR率

2014-05-15

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Hepatology：含SMV三联疗法治疗慢性1型丙肝安全有效

2014-02-16

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Hepatology：三联疗法或不再是丙肝标准方案 AASLD指南受挑战

2013-12-02

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

CID：三联疗法可有效预防接触MDR-TB的儿童感染肺结核

2013-10-01

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

含吡格列酮和艾塞那肽的三联疗法优于传统逐步递增治疗

2013-07-03

科室
- - 订阅+
  - 更多科室
工具
服务